The potential anti-Alzheimer's activity of Oxalis corniculata Linn. Methanolic extract in experimental rats: Role of APOE4/LRP1, TLR4/NF-κβ/NLRP3, Wnt 3/β-catenin/GSK-3β, autophagy and apoptotic cues

Abu-Elfotuh, Karema; Hamdan, Ahmed M.E.; Mohamed, Shaza A.; Bakr, Riham O.; Ahmed, Amal H.; Atwa, Ahmed M.; Hamdan, Amira M.; Alanzai, Ahad Ghanem; Alnahhas, Raghad Khalid; Gowifel, Ayah M.H.; Salem, Maha A.

doi:10.1016/j.jep.2024.117731

Cited by 2 publications

(1 citation statement)

References 105 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…LPS challenge and the consequent ROS increase significantly reduced Nrf2 and HO-1 expression, which act as key regulators in the protection mechanisms against oxidative stress with a fundamental role in antioxidant metabolism and response, as well as in the modulation of neuroinflammation [58][59][60]. Both levosimendan and dobutamine treatment showed an enhancement of Nrf2 and HO-1 expression compared to LPS-challenged cells; these results were in accordance with previous papers that showed a significant increase in the Nrf2/HO-1 pathway following dobutamine or levosimendan treatment in mice [14,61] and in rats [62].…”

Section: Discussionmentioning

confidence: 99%

Levosimendan and Dobutamin Attenuate LPS-Induced Inflammation in Microglia by Inhibiting the NF-κB Pathway and NLRP3 Inflammasome Activation via Nrf2/HO-1 Signalling

Mannino,

Urzì Brancati,

Lauro

et al. 2024

Biomedicines

View full text Add to dashboard Cite

Hypovolemic shock is a circulatory failure, due to a loss in the effective circulating blood volume, that causes tissue hypoperfusion and hypoxia. This condition stimulates reactive oxygen species (ROS) and pro-inflammatory cytokine production in different organs and also in the central nervous system (CNS). Levosimendan, a cardioprotective inodilator, and dobutamine, a β1-adrenergic agonist, are commonly used for the treatment of hypovolemic shock, thanks to their anti-inflammatory and antioxidant effects. For this reason, we aimed at investigating levosimendan and dobutamine’s neuroprotective effects in an “in vitro” model of lipopolysaccharide (LPS)-induced neuroinflammation. Human microglial cells (HMC3) were challenged with LPS (0.1 µg/mL) to induce an inflammatory phenotype and then treated with levosimendan (10 µM) or dobutamine (50 µM) for 24 h. Levosimendan and dobutamine significantly reduced the ROS levels and markedly increased Nrf2 and HO-1 protein expression in LPS-challenged cells. Levosimendan and dobutamine also decreased p-NF-κB expression and turned off the NLRP3 inflammasome together with its downstream signals, caspase-1 and IL-1β. Moreover, a reduction in TNF-α and IL-6 expression and an increase in IL-10 levels in LPS-stimulated HMC3 cells was observed following treatment. In conclusion, levosimendan and dobutamine attenuated LPS-induced neuroinflammation through NF-κB pathway inhibition and NLRP3 inflammasome activation via Nrf2/HO-1 signalling, suggesting that these drugs could represent a promising therapeutic approach for the treatment of neuroinflammation consequent to hypovolemic shock.

show abstract

Section: Discussionmentioning

confidence: 99%

Levosimendan and Dobutamin Attenuate LPS-Induced Inflammation in Microglia by Inhibiting the NF-κB Pathway and NLRP3 Inflammasome Activation via Nrf2/HO-1 Signalling

Mannino,

Urzì Brancati,

Lauro

et al. 2024

Biomedicines

View full text Add to dashboard Cite

show abstract

New Prospects of Alternative Medicine from Plant Sources in Management of Alzheimer’s Disease

Jepkosgei Kipkemoi

2024

Alternative Medicine - New Insights [Working Title]

View full text Add to dashboard Cite

Although the cure for Alzheimer’s disease (AD) remains elusive, the scientific community has remained vigilant in search of remedies for AD management. The statistics in the fight against AD paint a pale picture; the number of people suffering from Alzheimer’s disease remains high. About 40 million people worldwide, mainly the elderly, are experiencing AD and the number is expected to rise in the next decade. Meanwhile, FDA-certified drugs for AD management only relieve symptoms of the disease and provide a limited benefit to the cognitive functioning of the patient. The increasing economic and social burden as well as drawbacks of the current AD management measures highlights the need for urgent attention in search of alternative avenues to combat AD. A major area of focus in this endeavour is herbal therapy. Universally, humanity appreciably recognizes the role herbal medicines have played in catering to human health. Presently, 80% of the global populace relies on plant-based remedies for primary healthcare. Numerous herbal preparations have been reported to exhibit anti-AD efficacy in various research models. This chapter provides an account of AD pathophysiology and various herbal preparations with efficacy against AD in various study models: clinical trials, in vivo, in vitro and in silico.

show abstract

The potential anti-Alzheimer's activity of Oxalis corniculata Linn. Methanolic extract in experimental rats: Role of APOE4/LRP1, TLR4/NF-κβ/NLRP3, Wnt 3/β-catenin/GSK-3β, autophagy and apoptotic cues

Cited by 2 publications

References 105 publications

Levosimendan and Dobutamin Attenuate LPS-Induced Inflammation in Microglia by Inhibiting the NF-κB Pathway and NLRP3 Inflammasome Activation via Nrf2/HO-1 Signalling

Levosimendan and Dobutamin Attenuate LPS-Induced Inflammation in Microglia by Inhibiting the NF-κB Pathway and NLRP3 Inflammasome Activation via Nrf2/HO-1 Signalling

New Prospects of Alternative Medicine from Plant Sources in Management of Alzheimer’s Disease

Contact Info

Product

Resources

About